Antitumour Compounds
Publication number: US2009030068 (A1)
Publication date: 2009-01-29
Inventor(s): MARTIN LOPEZ MA JESUS [ES]; REYES BENITEZ JOSE FERNANDO [ES]; FERNANDEZ RODRIGUEZ ROGELIO [ES]; FRANCESCH SOLLOSO ANDRES [ES]; CUEVAS MARCHANTE MARIA DEL CARMEN [ES]; COELLO MOLINERO LAURA [ES]
Applicant(s): PHARMA MAR SA [ES]
Classification:
- international: A61K31/335; A61P35/00; C07D323/00; A61K31/335; A61P35/00; C07D323/00
- European: C07D493/18; C07D493/18
Application number: US20060097212 20061214
Priority number(s): ES20050003092 20051215; WO2006ES00687 20061214
View INPADOC patent family
View list of citing documents
Abstract of US 2009030068 (A1)
The invention relates to novel antitumor compounds of general formula as well as their corresponding pharmaceutically acceptable salts, derivatives, prodrugs and stereoisomers. These compounds can be obtained by isolating a sponge from family Theonellidae, genus Theonella and species swinhoei, and forming derivatives from the isolated compounds. These compounds have cytotoxic activity and can be used for the treatment of the cancer.
PharmaMar Recibe el Ok de la FDA Para Iniciar Fase I con PM54 en Combi con Inmuno Para Posible Tratamiento . PARA EI RELEVO DE LURBINECTEDIN ESTABAN PM184 Y PM14 AMBOS RETIRADOS POR LA CIA. AHORA HAY OTROS DOS FÁRMACOS EN FASE I EN EL INTENTO DE RELEVAR A LURBINECTEDIN : PM54 Y PM534 ... EL PROBLEMA ES QUE AMBOS AÚN ESTAN EN FASE I CON TODO LO QUE ESTO IMPLICA EN CUESTIÓN DE PLAZOS ... YA QUE PARA REALUZAR 3 FASES CLÍNICAS HACEN FALTA DE 12 A 15 AÑOS ... NOS IRÍAMOS AL 2040.